- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07943416
AI-Assisted Management of Diabetes and Hypertension in Primary Care
Brief Summary:
Many older adults in rural areas suffer from both type 2 diabetes and high blood pressure. Managing these two conditions at the primary care level is often challenging. This study aims to find out if a new "village doctor-led digital management model" can help improve patient health compared to the current standard care.
Who can participate? Adults aged 60 or older who have been diagnosed with both type 2 diabetes and high blood pressure, whose current blood sugar or blood pressure is not well-controlled, and who receive care at local village clinics.
How does the study work?
Village clinics will be randomly assigned to one of two groups:
Usual Care Group: Patients receive standard national primary health services.
Integrated Care Group: In addition to standard care, village doctors will use an Artificial Intelligence (AI) system. This system provides clinical suggestions to the village doctors, helps arrange remote consultations with hospital specialists if needed, and gives patients personalized advice on diet and exercise.
What are we measuring? We will follow participants for up to 3 years. The main goals are to see if the new AI-assisted model improves the control of blood sugar, blood pressure, and cholesterol at 12 months, and whether it reduces the risk of severe cardiovascular events (like heart attacks or strokes) over 36 months.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ming Chu
- Numéro de téléphone: 18061986120
- E-mail: 18061986120@189.cn
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
IInclusion Criteria:
Age ≥ 60 years. Previously diagnosed with both type 2 diabetes mellitus and hypertension. Inadequate glycemic control (HbA1c ≥ 7.5%; or HbA1c ≥ 8.0% if accompanied by clinical cardiovascular disease) OR inadequate blood pressure control (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg).
Signed a family doctor service agreement with the local village doctor. Agree to participate in the study and provide written informed consent.
Exclusion Criteria:
Severe physical or psychological problems. Unable to attend on-site visits. Unable to answer questions independently. Unable to reside in the participating community for more than 1 year. Life expectancy less than 3 years. Participated in any other clinical trial within the past 6 months.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Integrated Care Group
Village doctor-led integrated digital management, including LLM-assisted decision support, remote specialist collaboration, and individualized lifestyle intervention. |
A digital platform that integrates patient data and uses a large language model to provide risk alerts and management suggestions to village doctors for review. Village doctors can initiate remote consultations with specialists (e.g., endocrinology, cardiology) through the platform for complex or poorly controlled cases. Usual care according to the National Basic Public Health Service requirements. |
|
Autre: Usual Care Group
Usual care according to the National Basic Public Health Service requirements. |
Usual care according to the National Basic Public Health Service requirements. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of participants achieving at least 2 of 3 ABC goals at 12 months
Délai: 12 months post-randomization
|
The proportion of participants achieving at least two of the following three predefined goals at 12 months post-randomization: A (HbA1c control), B (Blood pressure control), and C (LDL-C control). |
12 months post-randomization
|
|
Time to first Major Adverse Cardiovascular Event (MACE) within 36 months
Délai: Up to 36 months post-randomization
|
The time from randomization to the first occurrence of a Major Adverse Cardiovascular Event (MACE) within 36 months. |
Up to 36 months post-randomization
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- LSKY 2026 -174-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .